FDA Extends Use of FOIA Identity Certification Form
Published Date: 6/23/2026
Notice
Summary
The FDA is asking for approval to keep using Form FDA 3975, which helps confirm who you are when you ask for your own records under the Freedom of Information Act or Privacy Act. If you want your personal info from the FDA but didn’t prove your identity well enough, this form steps in. Comments on this plan are open until July 23, 2026, and there’s no new cost for you—just a smoother way to get your info!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
FDA keeps identity form for record requests
The FDA will continue using Form FDA 3975, "Certification of Identity," to confirm who you are when you request your own records under the Freedom of Information Act or the Privacy Act. The form is required only when your original request did not provide sufficient assurance of identity and is associated with OMB Control Number 0910-0832.
Form asks for Social Security number and ID details
If you fill out Form FDA 3975, you are asked to provide name, citizenship status, Social Security number, address, date of birth, place of birth, a signature, and the date of signature. These specific personal identifiers are required as part of the identity certification process for FOIA and Privacy Act requests for your own records.
Very small time burden for requesters
The FDA estimates 24 total annual respondents completing Form FDA 3975, with each response taking about 0.17 hours (10 minutes) and a total annual burden of 4 hours. The agency states there are no capital costs or operating and maintenance costs associated with this information collection.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12577 — Agency Information Collection Activities; Proposed Collection; Comment Request; Potential Tobacco Product Violations Reporting Form
The FDA wants your thoughts on a new form to report possible tobacco product rule-breakers. This affects anyone who might spot tobacco violations and helps the FDA keep products safe. You’ve got until August 24, 2026, to share your comments—no cost to you, just your voice!
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
Previous / Next Documents
Previous: 2026-12577 — Agency Information Collection Activities; Proposed Collection; Comment Request; Potential Tobacco Product Violations Reporting Form
The FDA wants your thoughts on a new form to report possible tobacco product rule-breakers. This affects anyone who might spot tobacco violations and helps the FDA keep products safe. You’ve got until August 24, 2026, to share your comments—no cost to you, just your voice!
Next: 2026-12580 — Notice of Final Federal Agency Actions on Proposed Highway Projects in Texas
The Texas Department of Transportation and federal agencies have given the green light to several new highway projects across Texas. These projects now have all the necessary permits and approvals to move forward, affecting drivers, local communities, and businesses. If anyone wants to challenge these decisions, they must do so by November 20, 2026, or lose their chance.